Marc Bourlière
Impact in
- Hepatology top 0.02%
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Liver physiology and pathology
- Epidemiology top 0.2%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
Papers in
- Hepatology 319
- Hepatitis C virus research 254
- Hepatocellular Carcinoma Treatment and Prognosis 39
- Liver Disease and Transplantation 19
- Liver Diseases and Immunity 8
- Epidemiology 115
- Hepatitis B Virus Studies 65
- Liver Disease Diagnosis and Treatment 49
- Co-authors
- Philippe Halfon (88 shared papers)Stanislas Pol (56 shared papers)Guillaume Pénaranda (60 shared papers)Jean–Pierre Bronowicki (38 shared papers)Denis Ouzan (43 shared papers)Christophe Hézode (24 shared papers)Victor de Lédinghen (44 shared papers)Laurent Castéra (16 shared papers)
- Journals
- Journal of Hepatology (101 papers)Liver International (28 papers)Hepatology (18 papers)Gastroenterology (18 papers)Journal of Viral Hepatitis (17 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Marc Bourlière
414 papers receiving 20.5k citations
Marc Bourlière's Hit Papers
Peers
Comparison fields: 5 of 142
- Hepatology 13.1k
- Epidemiology 6.2k
- Biotechnology 247
- Pharmacology 204
- Hematology 245
Countries citing papers authored by Marc Bourlière
This map shows the geographic impact of Marc Bourlière's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Bourlière with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Bourlière more than expected).
Fields of papers citing papers by Marc Bourlière
This network shows the impact of papers produced by Marc Bourlière. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Bourlière. The network helps show where Marc Bourlière may publish in the future.
Co-authors
The 25 scholars most cited alongside Marc Bourlière, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 435 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2019 | 1078 |
| 2 | Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Hit paper breakdown → | 2016 | 916 |
| 3 | Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection Hit paper breakdown → | 2009 | 856 |
| 4 | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection Hit paper breakdown → | 2015 | 699 |
| 5 | Advancing the global public health agenda for NAFLD: a consensus statement Hit paper breakdown → | 2021 | 600 |
| 6 | Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study Hit paper breakdown → | 2019 | 500 |
| 7 | 2003 | 464 | |
| 8 | Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection Hit paper breakdown → | 2017 | 453 |
| 9 | Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin Hit paper breakdown → | 2014 | 446 |
| 10 | Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications Hit paper breakdown → | 2016 | 438 |
| 11 | Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Hit paper breakdown → | 2020 | 414 |
| 12 | Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study Hit paper breakdown → | 2017 | 397 |
| 13 | 2007 | 376 | |
| 14 | 2013 | 375 | |
| 15 | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 374 |
| 16 | Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection Hit paper breakdown → | 2018 | 340 |
| 17 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 326 |
| 18 | 2014 | 298 | |
| 19 | 2007 | 258 | |
| 20 | 2015 | 249 |
About Marc Bourlière
Marc Bourlière is a scholar working on Hepatology, Epidemiology, Pharmacology, Infectious Diseases and Pharmacology, having authored 435 papers that have together received 21.2k indexed citations. Recurring topics across this work include Hepatitis C virus research (254 papers), Hepatitis B Virus Studies (65 papers), Liver Disease Diagnosis and Treatment (49 papers), Hepatocellular Carcinoma Treatment and Prognosis (39 papers), Liver Disease and Transplantation (19 papers), Liver Diseases and Immunity (8 papers), Drug-Induced Hepatotoxicity and Protection (6 papers) and HIV/AIDS drug development and treatment (4 papers). The work is most often cited by research in Hepatology (13.1k citations), Epidemiology (6.2k citations), Biotechnology (247 citations), Pharmacology (204 citations) and Hematology (245 citations). Marc Bourlière has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Philippe Halfon, Stanislas Pol, Guillaume Pénaranda, Jean–Pierre Bronowicki, Denis Ouzan, Christophe Hézode, Victor de Lédinghen, Laurent Castéra, Geoffrey M Dusheiko and Christophe Renou. Their work appears in journals such as Journal of Hepatology, Liver International, Hepatology, Gastroenterology and Journal of Viral Hepatitis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.